Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.78 |
| ▸ | RAB9A | P51151 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664663 | 0.91 | MEN1 (0.72) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL18407544 | 0.88 | NPC1 (0.78) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL11688832 | 0.87 | NPC1 (0.60) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL11693468 | 0.87 | NPC1 (0.60) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL4256379 | 0.86 | NPC1 (0.76) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL95558 | 0.86 | NPC1 (0.76) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL5492048 | 0.86 | RAB9A (0.75) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL9696412 | 0.85 | NR1H4 (0.77) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL14363190 | 0.84 | KCNK3 (0.68) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL5888834 | 0.82 | NPC1 (0.61) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | NPC1 297/4885RAB9A 3975/4885ALDH1A1 591/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885ALDH1A1 204/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NPC1 87/4885RAB9A 2829/4885ALDH1A1 1497/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NPC1 87/4885RAB9A 2829/4885ALDH1A1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.